RSS Events Feeds

Webinar On Current GMP Requirements for Combination Products Final Rule

9/4/2014 1:00 PM - 2:30 PM

As you know, medical diagnosis, technology, and treatment is very dynamic and is rapidly advancing. New discoveries are made that do not fit the "regulatory mold “and thus require new approaches to regulation. Combination products is one such area that has grown proportionally as technology advances creating in the need to rethink the processes for classification, design, quality assurance, and regulatory approval of such products. This challenges industry and the FDA to develop strategies for effectively working together to meet user and customer needs. As a professional, you are aware of the complexities of also combining the regulatory, business, and quality processes to make such products a reality.

To deal with these complexities, the FDA published draft guidance for the application of GMP to combination products. The FDA determined that these requirements should be formalized in the Federal Register. The proposed rule was published in 2009 and the final rule was published on December 22, 2012 and was effective July 22, 2013. This webinar discusses this final rule and describes approaches to comply.

At the end of this session, you will be able

To understand where the combination products GMP rule applies.

To learn & understand the differences between drugs, biologicals comments and after devices & their modes of actions

To understand how they interact to produce combination products

To learn and understand how to apply the regulation to your product and operations

To gain additional perspective on how to apply quality principles to solve compliance problems

Areas Covered in the Session :

Objectives & Overview

The Draft Guidance vs. The Proposed Rule Vs. The Final Rule

A quick review of the Pharmaceutical, Medical Device, and Biological GMP Contents

A Quick Overview and Analysis Of Industry Comments and the FDA Responses

Who is in charge of your product CDER,CBER,CDRH

Scope, applicability and factors that impact the manufacturing

Quality and compliance perspectives of the Final Rule

FDA's discretionary enforcement of the Final Rule

Reviewing, Analyzing, & Understanding the Final Rule

21 CFR Part 4, Subpart A

Practical Suggestions for complying with Combination Product cGMP Subparts

Beyond the regulation and its impact

Who Will Benefit:

QA / QC Managers and personnel

Regulatory Affairs

Product Management

Supervisors & Group Leaders

Production Management

Companies new to the FDA regulated industry


Compliance Management

Quality Unit Vice Presidents & Directors

Vice presidents, Directors and Managers of Operations


Price Tags:


Single Live : For One Participant

$ 249

Corporate Live : For Max. 10 Participants

$ 899


Single REC : For One Participant - Unlimited Access for 6 Months

$ 299

Learn More: Webinar On Current GMP Requirements for Combination Products Final Rule

Events Map

Email Newsletters

Want to be up-to-date with the latest news and updates from To subscribe, just give us your email address below; you'll choose which e-newsletters you'd like to receive on the next screen.